Skip to main content
Top
Published in: Thrombosis Journal 1/2024

Open Access 01-12-2024 | Phlebothrombosis | Research

Causes of death after first time venous thromboembolism

Authors: Frida Lonnberg, Andreas Roos, Maria Farm, André Heurlin, Mantas Okas, Bruna Gigante, Anwar J Siddiqui

Published in: Thrombosis Journal | Issue 1/2024

Login to get access

Abstract

Background

Causes of death after first time community-acquired venous thromboembolism (VTE) diagnosed in unselected patients at the emergency department (ED) was investigated.

Materials and methods

The study consists of all patients > 18 years of age who had a visit for any medical reason to any of 5 different ED in Stockholm County, Sweden from 1st January 2016 to 31st December 2017. We have identified all patients with a first registered incident VTE; deep vein thrombosis (DVT) and/or pulmonary embolism (PE) during the study period. Cox regression models were used to estimate hazards ratios (HR) with 95% confidence intervals (CIs) for all-cause mortality and cause-specific death in patients with DVT or PE using all other patients as the reference group.

Results

In total, 359,884 patients had an ED visit during the study period of whom about 2.1% were diagnosed with VTE (DVT = 4,384, PE = 3,212). The patients with VTE were older compared to the control group. During a mean follow up of 2.1 years, 1567 (21%) and 23,741(6.7%) patients died within the VTE and reference group, respectively. The adjusted risk of all-cause mortality was nearly double in patients with DVT (HR 1.7; 95% CI, 1.5–1.8) and more than 3-fold in patients with PE (HR 3.4; 95% CI, 3.1–3.6). While the risk of cancer related death was nearly 3-fold in patient with DVT (HR 2.7; 95% CI, 2.4–3.1), and 5-fold in PE (HR 5.4; 95% CI, 4.9-6.0 respectively). The diagnosis of PE during the ED visit was associated with a significantly higher risk of cardiovascular death (HR 2.2; 95% CI, 1.9–2.6).

Conclusion

Patients with VTE have an elevated risk of all-cause mortality, including cardiovascular death.
Appendix
Available only for authorised users
Literature
1.
go back to reference Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060–73.CrossRefPubMed Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060–73.CrossRefPubMed
2.
go back to reference Deitelzweig SB, Johnson BH, Lin J. Prevalence of clinical venous thromboembolism in the USA:current trends and future projections. Am J Hematol. 2011;86(2):217–9.CrossRefPubMed Deitelzweig SB, Johnson BH, Lin J. Prevalence of clinical venous thromboembolism in the USA:current trends and future projections. Am J Hematol. 2011;86(2):217–9.CrossRefPubMed
3.
go back to reference Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009). Am J Med. 2014;127(9):829–839e5.CrossRefPubMedPubMedCentral Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009). Am J Med. 2014;127(9):829–839e5.CrossRefPubMedPubMedCentral
4.
go back to reference Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 2020;41(4):543–603.CrossRefPubMed Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 2020;41(4):543–603.CrossRefPubMed
5.
go back to reference Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, et al. American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–738.CrossRefPubMedPubMedCentral Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, et al. American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–738.CrossRefPubMedPubMedCentral
6.
go back to reference Søgaard KK, Schmidt M, Pedersen L, Horváth-Puhó E, Sørensen HT. 30-Year mortality after venous thromboembolism a population-based cohort study. Circulation. 2014;130(10):829–36.CrossRefPubMed Søgaard KK, Schmidt M, Pedersen L, Horváth-Puhó E, Sørensen HT. 30-Year mortality after venous thromboembolism a population-based cohort study. Circulation. 2014;130(10):829–36.CrossRefPubMed
7.
go back to reference Faller N, Limacher A, Méan M, Righini M, Aschwanden M, et al. Predictors and causes of Long-Term Mortality in Elderly patients with acute venous thromboembolism: a prospective cohort study. Am J Med. 2017;130(2):198–206.CrossRefPubMed Faller N, Limacher A, Méan M, Righini M, Aschwanden M, et al. Predictors and causes of Long-Term Mortality in Elderly patients with acute venous thromboembolism: a prospective cohort study. Am J Med. 2017;130(2):198–206.CrossRefPubMed
8.
go back to reference Kraaijpoel N, Tritschler T, Guillo E, Girard P, Le Gal G. Definitions, adjudication, and reporting of pulmonary embolism–related death in clinical studies: a systematic review. J Thromb Haemost. 2019;17(10):1590–607.CrossRefPubMed Kraaijpoel N, Tritschler T, Guillo E, Girard P, Le Gal G. Definitions, adjudication, and reporting of pulmonary embolism–related death in clinical studies: a systematic review. J Thromb Haemost. 2019;17(10):1590–607.CrossRefPubMed
9.
go back to reference Klemen ND, Feingold PL, Hashimoto B, Wang M, Kleyman S, Brackett A, et al. Mortality risk associated with venous thromboembolism: a systematic review and bayesian meta-analysis. Lancet Haematol. 2020;7(8):e583–93. 016/S.CrossRefPubMed Klemen ND, Feingold PL, Hashimoto B, Wang M, Kleyman S, Brackett A, et al. Mortality risk associated with venous thromboembolism: a systematic review and bayesian meta-analysis. Lancet Haematol. 2020;7(8):e583–93. 016/S.CrossRefPubMed
10.
go back to reference Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: The Q-VTE study cohort. Am J Med. 2013;126(9):832.e13-832.e21. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: The Q-VTE study cohort. Am J Med. 2013;126(9):832.e13-832.e21.
11.
go back to reference Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor. Arch Intern Med. 2010;170(19):1710–6.PubMed Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor. Arch Intern Med. 2010;170(19):1710–6.PubMed
12.
go back to reference Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, et al. ISTH Steering Committee for World thrombosis day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363–71.CrossRefPubMed Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, et al. ISTH Steering Committee for World thrombosis day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363–71.CrossRefPubMed
13.
go back to reference Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, et al. All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism. Thromb Haemost. 2018;118(9):1637–45.CrossRefPubMedPubMedCentral Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, et al. All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism. Thromb Haemost. 2018;118(9):1637–45.CrossRefPubMedPubMedCentral
14.
go back to reference Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, et al. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res. 2020;191(March):103–12.CrossRefPubMed Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, et al. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res. 2020;191(March):103–12.CrossRefPubMed
15.
go back to reference Næss IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9.CrossRefPubMed Næss IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9.CrossRefPubMed
16.
go back to reference Arshad N, Bjøri E, Hindberg K, Isaksen T, Hansen JB, Brækkan SK. Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost. 2017;15(2):295–303.CrossRefPubMed Arshad N, Bjøri E, Hindberg K, Isaksen T, Hansen JB, Brækkan SK. Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost. 2017;15(2):295–303.CrossRefPubMed
17.
go back to reference Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131(1):24–30.CrossRefPubMed Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131(1):24–30.CrossRefPubMed
18.
go back to reference Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, et al. Case Fatality Rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism. J Cardiovasc Pharmacol Ther. 2015;20(5):490–500.CrossRefPubMed Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, et al. Case Fatality Rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism. J Cardiovasc Pharmacol Ther. 2015;20(5):490–500.CrossRefPubMed
19.
go back to reference Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50.CrossRefPubMed Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50.CrossRefPubMed
21.
go back to reference Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–73.CrossRefPubMedPubMedCentral Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–73.CrossRefPubMedPubMedCentral
22.
go back to reference Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (multicenter emergency medicine pulmonary embolism in the real world registry). J Am Coll Cardiol [Internet]. 2011;57(6):700–6.CrossRefPubMed Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (multicenter emergency medicine pulmonary embolism in the real world registry). J Am Coll Cardiol [Internet]. 2011;57(6):700–6.CrossRefPubMed
23.
go back to reference Chwan Ng AC, Chung T, Yong ASC, Wong HSP, Celermajer DS, et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes. 2011;4(1):122–8.CrossRef Chwan Ng AC, Chung T, Yong ASC, Wong HSP, Celermajer DS, et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes. 2011;4(1):122–8.CrossRef
24.
go back to reference Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost. 2010;8(5):891–7.CrossRefPubMed Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost. 2010;8(5):891–7.CrossRefPubMed
25.
go back to reference Mi Y, Yan S, Lu Y, Liang Y, Li C. Venous thromboembolism has the same risk factors as atherosclerosis. Med (Baltim). 2016;95(32):e4495.CrossRef Mi Y, Yan S, Lu Y, Liang Y, Li C. Venous thromboembolism has the same risk factors as atherosclerosis. Med (Baltim). 2016;95(32):e4495.CrossRef
26.
go back to reference Barco S, Mahmoudpour SH, Valerio L, Klok FA, Münzel T, et al. Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med. 2020;8(3):277–87.CrossRefPubMed Barco S, Mahmoudpour SH, Valerio L, Klok FA, Münzel T, et al. Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med. 2020;8(3):277–87.CrossRefPubMed
27.
go back to reference Wallerstedt SM, Wettermark B, Hoffmann M. The First Decade with the Swedish Prescribed Drug Register-A Systematic Review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464–9.CrossRefPubMed Wallerstedt SM, Wettermark B, Hoffmann M. The First Decade with the Swedish Prescribed Drug Register-A Systematic Review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464–9.CrossRefPubMed
28.
go back to reference Fastbom J, Johnell K. National indicators for quality of drug therapy in older persons: the Swedish experience from the first 10 years. Drugs Aging. 2015;32:189–99.CrossRefPubMedPubMedCentral Fastbom J, Johnell K. National indicators for quality of drug therapy in older persons: the Swedish experience from the first 10 years. Drugs Aging. 2015;32:189–99.CrossRefPubMedPubMedCentral
29.
go back to reference Wallerstedt SM, Belfrage B, Fastbom J. Association between drug specific indicators of prescribing quality and quality of drug treatment: a validation study. Pharmacoepidemiol Drug Saf. 2016;24:906–14.CrossRef Wallerstedt SM, Belfrage B, Fastbom J. Association between drug specific indicators of prescribing quality and quality of drug treatment: a validation study. Pharmacoepidemiol Drug Saf. 2016;24:906–14.CrossRef
30.
go back to reference Öhman L, Johansson M, Jansson JH, Lind M, Johansson L. Positive predictive value and misclassification of diagnosis of pulmonary embolism and deep vein thrombosis in Swedish patient registries. Clin Epidemiol. 2018;10:1215–21.CrossRefPubMedPubMedCentral Öhman L, Johansson M, Jansson JH, Lind M, Johansson L. Positive predictive value and misclassification of diagnosis of pulmonary embolism and deep vein thrombosis in Swedish patient registries. Clin Epidemiol. 2018;10:1215–21.CrossRefPubMedPubMedCentral
Metadata
Title
Causes of death after first time venous thromboembolism
Authors
Frida Lonnberg
Andreas Roos
Maria Farm
André Heurlin
Mantas Okas
Bruna Gigante
Anwar J Siddiqui
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2024
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-024-00586-8

Other articles of this Issue 1/2024

Thrombosis Journal 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.